Article Details
Retrieved on: 2025-10-03 14:12:17
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
FDA approves Roche's Tecentriq + lurbinectedin for first-line maintenance in ES‑SCLC. IMforte: 46% lower progression/death and 27% lower death; ...
Article found on: www.stocktitan.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here